Startseite Kongressberichte 2020 61st ASH Annual Meeting and Exposition Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies Mantle Cell Lymphoma: Frontline and Relapsed Therapies

623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Mantle Cell Lymphoma: Frontline and Relapsed Therapies

751
Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

Mitchell Smith, et al.

Conclusion cited from the abstract: Both NGS and FC were feasible to assess MRD status in this multi-center trial. Results of NGS and FC are concordant at the 10-4 cutoff. NGS can be more sensitive when adequate material is available, and analysis of this subgroup is ongoing. The high MRD- rate (≥ 90%) at EOI in this BR-based trial and MRD correlation with PFS supports its use as a platform for MCL trials, although consolidation may confound PFS. Early interim MRD testing at cycle 3 identifies a high-risk population who may benefit from alternative treatment strategies. Analysis by treatment arm with longer follow-up, as well as comparison with centrally reviewed PET/CTs included in this study, will help define the most informative method(s), cutoff values, and timing for assessing degree of response in MCL.

Double-click
 

 

752
Efficacy and Safety of Ibrutinib in Combination with Rituximab As Frontline Treatment for Indolent Clinical Forms of Mantle Cell Lymphoma (MCL): Preliminary Results of Geltamo IMCL-2015 Phase II Trial

Eva Gine, et al. 

Conclusion cited from the abstract: 

In indolent clinical forms of MCL frontline ibrutinib in combination with rituximab has a high efficacy, including undetectable MRD in the majority of cases, with a predictable toxicity profile.

Double-click:

 

 
753
Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma

David A. Bond, et al. 

Conclusion cited from the abstract: 

Time to relapse is predictive of outcome in pts with MCL and outcomes with current salvage therapies are poor for pts with relapse within 6 months of frontline therapy. Of currently available second line therapies, BTKi were associated with improved PFS2 in refractory pts. Outcomes are particularly poor for pts who receive intensive induction therapies yet still relapse early, representing a population at high risk for early mortality related to MCL. Novel treatment approaches should be evaluated in this population, including CAR-T cell therapy, and attempts to improve risk stratification at diagnosis and develop improved therapies for high-risk pts should continue.

Double-click:

 

 

754
KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study

Michael L. Wang, et al. 

Conclusion cited from the abstract: 

ZUMA-2 is the first multicenter Phase 2 study of CAR T cell therapy in pts with R/R MCL. With ≥ 1 year of follow-up, KTE-X19 demonstrated significant and durable clinical benefit, including a majority of pts achieving CR, and a manageable safety profile in pts with R/R MCL for whom there are no curative treatment options.

 

755
Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study

Yuqin Song, et al. 

Conclusion cited from the abstract: 

Orelabrutinib is safe and well tolerated with no reported treatment related grade 3 or higher GI toxicity, atrial fibrillation/flutter and severe bleeding in this study. Orelabrutinib is efficacious to treat patients with r/r MCL. The improved safety, resulting from high target selectivity, and the convenience of daily dosing regimen provides orelabrutinib as the potential of preferred therapeutic choice for B cell malignancy.

 

 

756
Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study

Sasanka M. Handunnetti, et al. 

Conclusion cited from the abstract: 

The median PFS for the IB-VEN combination was 29 months. Treatment interruption was feasible for pts in MRD-negative complete remissions, raising the prospect of limited duration targeted-agent therapy in the management of R/R MCL.

Double-click: